Nonclinical safety evaluation, pharmacokinetics, and target engagement of Lu AF82422, a monoclonal IgG1 antibody against alpha-synuclein in development for treatment of synucleinopathies

Alpha-synuclein is a 15 kDa protein associated with neurodegenerative diseases such as Parkinson disease and multiple-system atrophy where pathological forms of alpha-synuclein aggregate and become neurotoxic. Here we describe the nonclinical program to support a first-in-human (FIH) single ascendin...

Descripción completa

Detalles Bibliográficos
Autores principales: Fjord-Larsen, Lone, Thougaard, Annemette, Wegener, Karen Malene, Christiansen, Joan, Larsen, Frank, Schrøder-Hansen, Lise Maj, Kaarde, Marianne, Ditlevsen, Dorte Kornerup
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555527/
https://www.ncbi.nlm.nih.gov/pubmed/34709986
http://dx.doi.org/10.1080/19420862.2021.1994690

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555527/
https://www.ncbi.nlm.nih.gov/pubmed/34709986
http://dx.doi.org/10.1080/19420862.2021.1994690

Ejemplares similares